KR102609431B1 - Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 - Google Patents

Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 Download PDF

Info

Publication number
KR102609431B1
KR102609431B1 KR1020177030091A KR20177030091A KR102609431B1 KR 102609431 B1 KR102609431 B1 KR 102609431B1 KR 1020177030091 A KR1020177030091 A KR 1020177030091A KR 20177030091 A KR20177030091 A KR 20177030091A KR 102609431 B1 KR102609431 B1 KR 102609431B1
Authority
KR
South Korea
Prior art keywords
triazolo
pyridin
benzonitrile
cyano
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177030091A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129874A (ko
Inventor
살레 아메드
그레고리 바커
한나 캐닝
리처드 데이븐포트
데이비드 해리슨
케리 젠킨스
데이비드 리버모어
수잔 라이트
나타샤 킨셀라
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20170129874A publication Critical patent/KR20170129874A/ko
Application granted granted Critical
Publication of KR102609431B1 publication Critical patent/KR102609431B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177030091A 2015-03-18 2016-03-17 Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 Active KR102609431B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
GB1504565.1 2015-03-18
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (2)

Publication Number Publication Date
KR20170129874A KR20170129874A (ko) 2017-11-27
KR102609431B1 true KR102609431B1 (ko) 2023-12-04

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030091A Active KR102609431B1 (ko) 2015-03-18 2016-03-17 Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718902C2 (ru) 2016-02-24 2020-04-15 Пфайзер Инк. Производные пиразоло[1,5-а]пиразин-4-ила в качестве jak-ингибиторов
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
US20230322717A1 (en) * 2020-04-20 2023-10-12 Shenzhen Targetrx, Inc. Solid form of pyrazine substituted nicotinamide, and preparation and use thereof
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
IL312220A (en) 2021-10-28 2024-06-01 Insilico Medicine Ip Ltd Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077267A1 (en) 2009-07-17 2011-03-31 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
WO2011090127A1 (ja) 2010-01-21 2011-07-28 石原産業株式会社 トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2014030716A1 (ja) 2012-08-23 2014-02-27 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
JP2004502691A (ja) 2000-06-30 2004-01-29 ワイス 抗癌薬としての置換トリアゾロピリミジン
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077267A1 (en) 2009-07-17 2011-03-31 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
WO2011090127A1 (ja) 2010-01-21 2011-07-28 石原産業株式会社 トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2014030716A1 (ja) 2012-08-23 2014-02-27 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
CA2979024A1 (en) 2016-09-22
DK3271357T3 (da) 2020-02-17
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
SG11201707280VA (en) 2017-10-30
PE20180656A1 (es) 2018-04-17
EP3271357A1 (en) 2018-01-24
ZA201706612B (en) 2019-01-30
CL2017002354A1 (es) 2018-05-04
UA123668C2 (uk) 2021-05-12
EP3271357B1 (en) 2019-11-27
CN107531698A (zh) 2018-01-02
CN107531698B (zh) 2024-08-13
MX2017011902A (es) 2017-12-15
BR112017019653B1 (pt) 2023-10-03
NZ735631A (en) 2023-07-28
GB201504565D0 (en) 2015-05-06
DOP2017000209A (es) 2017-10-15
HUE047918T2 (hu) 2020-05-28
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
CA2979024C (en) 2024-02-20
CO2017009353A2 (es) 2017-11-30
TN2017000384A1 (en) 2019-01-16
IL254277A0 (en) 2017-10-31
IL254277B (en) 2020-10-29
BR112017019653A2 (pt) 2018-05-15
AU2016234209A1 (en) 2017-10-12
AU2016234209B2 (en) 2020-08-27
JP2018512408A (ja) 2018-05-17
WO2016148306A1 (en) 2016-09-22
US20180072714A1 (en) 2018-03-15
US10287286B2 (en) 2019-05-14
GEP20207095B (en) 2020-04-10
MY194873A (en) 2022-12-21
EA035739B1 (ru) 2020-08-03
ES2774052T3 (es) 2020-07-16
PT3271357T (pt) 2020-02-21
KR20170129874A (ko) 2017-11-27
JP6726681B2 (ja) 2020-07-22
ECSP17069696A (es) 2018-02-28
PH12017501699B1 (en) 2023-06-30

Similar Documents

Publication Publication Date Title
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
TW202214605A (zh) 免疫調節劑、組合物及其方法
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
ES2463676T3 (es) Inhibidor de la producción de quinurenina
JP2020525522A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
KR20190092538A (ko) C-kit 억제제로서의 벤즈이미다졸 화합물
KR20190091537A (ko) C-kit 억제제로서의 아미노티아졸 화합물
CN114423753A (zh) 作为cd38抑制剂的杂双环酰胺
CN110573501A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CA2799146A1 (en) Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
US11944622B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
WO2022173033A1 (ja) ４－アミノキナゾリン化合物
KR20230112605A (ko) 키나아제 억제제 및 그의 용도
WO2015134171A1 (en) Heteroarylamide inhibitors of tbk1
AU2024225909A1 (en) Covalent modifiers of akt1 and uses thereof
HK1249512B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
WO2025059562A1 (en) Substituted aminopyridine compounds and methods of treating disease using same
EP4653437A2 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000